| ［1］ |
Vasudevan B, Neema S, Verma R. Livedoid vasculopathy: a review of pathogenesis and principles of management［J］. Indian J Dermatol Venereol Leprol, 2016,82（5）:478⁃488. doi: 10.4103/0378⁃6323.183635.
|
| ［2］ |
Lee JS, Cho S. Livedoid vasculopathy in Koreans: clinical features and response to rivaroxaban treatment［J］. J Eur Acad Dermatol Venereol, 2020,34（4）:e176⁃e178. doi: 10.1111/jdv. 16129.
|
| ［3］ |
Rujitharanawong C, Chularojanamontri L, Trakanwittayarak S, et al. Livedoid vasculopathy: clinical course and long⁃term outcome in Asian patients with a review of the literature［J］. Dermatol Ther, 2021,34（1）:e14569. doi: 10.1111/dth.14569.
|
| ［4］ |
Huang XW, Zheng HX, Wang ML, et al. Adalimumab in treating refractory livedoid vasculopathy［J］. Vaccines （Basel）, 2022,10（4）:549. doi: 10.3390/vaccines10040549.
|
| ［5］ |
Page MJ, Bester J, Pretorius E. The inflammatory effects of TNF⁃α and complement component 3 on coagulation［J］. Sci Rep, 2018,8（1）:1812. doi: 10.1038/s41598⁃018⁃20220⁃8.
|
| ［6］ |
Manfredi AA, Baldini M, Camera M, et al. Anti⁃TNFα agents curb platelet activation in patients with rheumatoid arthritis［J］. Ann Rheum Dis, 2016,75（8）:1511⁃1520. doi: 10.1136/annrheumdis⁃ 2015⁃208442.
|
| ［7］ |
Ueda A, Takeno M, Ishigatsubo Y. Adalimumab in the management of Behçet's disease［J］. Ther Clin Risk Manag, 2015,11:611⁃619. doi: 10.2147/TCRM.S56163.
|
| ［8］ |
Koberová R, Merglová V, Radochová V. Recurrent aphthous stomatitis in children: a practical guideline for paediatric practitioners［J］. Acta Medica （Hradec Kralove）, 2020,63（4）:145⁃149. doi: 10.14712/18059694.2020.56.
|
| ［9］ |
Gao Y, Jin H. Efficacy of an anti⁃TNF⁃alpha agent in refractory livedoid vasculopathy: a retrospective analysis［J］. J Dermatolog Treat, 2022,33（1）:178⁃183. doi: 10.1080/09546634.2020.173 7634.
|
| ［10］ |
Bilgic A, Ozcobanoglu S, Bozca BC, et al. Livedoid vasculopathy: a multidisciplinary clinical approach to diagnosis and management［J］. Int J Womens Dermatol, 2021,7（5Part A）:588⁃599. doi: 10.1016/j.ijwd.2021.08.013.
|
